Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
boston blog main
inclisiran
5
×
life sciences
national blog main
new york blog main
new york top stories
regeneron pharmaceuticals
boston top stories
clinical trials
national top stories
new york
alirocumab
alnylam pharmaceuticals
biotech
cholesterol
evolocumab
pcsk9
pcsk9 inhibitors
praluent
repatha
sanofi
heart attack
ldl
medicines co.
mt sinai hospital
prashant vaishnava
rna interference
san francisco blog main
san francisco top stories
stroke
the medicines co.
boulder/denver blog main
boulder/denver top stories
cardiac
cardiovascular
cause of death
cedar-sinai
circulation
clinical studies
What
cholesterol
drug
5
×
lowering
medco
medicines
new
fda
twice
wave
aces
acquire
agreed
alnylam
announced
based
big
billion
bringing
brings
cash
ceo
clears
closer
company
compound
data
deal
drugs
evidence
expensive
faces
filing
financial
flexible
foe
healthcare
heart
hint
inched
inclisiran
Language
unset
Current search:
inclisiran
×
drug
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms